SCHEMBL14596197

SCHEMBL14596197

COc1ccccc1NC(=O)N(C)Cc1nc(NCCCN(C)C)c2ccccc2n1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 6/20 0.52
FLT3 P36888 3/20 0.50
POLB P06746 2/20 0.49
RXFP1 Q9HBX9 1/20 0.49
KDM1A O60341 3/20 0.49
EHMT2 Q96KQ7 3/20 0.49
RCOR1 Q9UKL0 3/20 0.49
USP2 O75604 1/20 0.48
TSHR P16473 1/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPK1 P28482 1/20 0.48
ACHE P22303 2/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
TERT O14746 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
TOP2A P11388 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13159157 0.90 TERT (0.50) RAD52FLT3POLBRXFP1ACHE
SCHEMBL14596211 0.88 ALDH1A1 (0.50) RAD52FLT3POLBRXFP1KDM1A
SCHEMBL14596188 0.87 ALDH1A1 (0.49) RAD52FLT3POLBRXFP1ALDH1A1
SCHEMBL14596200 0.87 POLB (0.51) RAD52FLT3POLBRXFP1ALDH1A1
SCHEMBL14596213 0.86 RAD52 (0.53) RAD52FLT3POLBRXFP1KDM1A
SCHEMBL14596198 0.86 RAD52 (0.52) RAD52FLT3POLBRXFP1KDM1A
SCHEMBL14596061 0.85 FLT3 (0.52) RAD52FLT3POLBRXFP1KDM1A
SCHEMBL14596215 0.85 ALDH1A1 (0.47) RAD52FLT3POLBRXFP1USP2
SCHEMBL14596189 0.83 FLT3 (0.56) RAD52FLT3POLBRXFP1ALDH1A1
SCHEMBL14596195 0.82 RAD52 (0.50) RAD52FLT3POLBRXFP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment TP53, TP53BP1, ACIN1 RAD52 954/4885FLT3 191/4885POLB 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.